Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

News Daily News

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Michael O'Riordan

December 06, 2023

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

News Conference News AHA 2023

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

November 13, 2023

Evinacumab Helps Severe Hypercholesterolemia Patients Reach LDL Targets

News Daily News

Evinacumab Helps Severe Hypercholesterolemia Patients Reach LDL Targets

Michael O'Riordan

September 14, 2023

ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran

News Conference News ESC 2023

ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran

Michael O'Riordan

September 01, 2023

LDL Control Remains Poor in CAD Patients: NHANES

News Daily News

LDL Control Remains Poor in CAD Patients: NHANES

Michael O'Riordan

July 05, 2023

Variable Response to Novel PCSK9 Inhibitor Lerodalcibep in LIBERATE-HoFH

News Conference News EAS 2023

Variable Response to Novel PCSK9 Inhibitor Lerodalcibep in LIBERATE-HoFH

Michael O'Riordan

May 24, 2023

High LDL, Poor Treatment, Early Death: HoFH Registry Paints Grim Picture

News Conference News EAS 2023

High LDL, Poor Treatment, Early Death: HoFH Registry Paints Grim Picture

Michael O'Riordan

May 23, 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

News Conference News ACC 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Michael O'Riordan

March 04, 2023

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

News Daily News

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Michael O'Riordan

January 16, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.